(Q36523494)

English

Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature

scientific article published on April 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature (English)

1 reference

Europe PubMed Central

14 August 2017

author name string

Johann C Brandes

1

1 reference

Europe PubMed Central

14 August 2017

Stuart A Grossman

2

1 reference

Europe PubMed Central

14 August 2017

Homaa Ahmad

3

1 reference

Europe PubMed Central

14 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2006

1 reference

Europe PubMed Central

14 August 2017

Cancer Investigation

1 reference

Europe PubMed Central

14 August 2017

24

1 reference

Europe PubMed Central

14 August 2017

3

1 reference

Europe PubMed Central

14 August 2017

283-287

1 reference

Europe PubMed Central

14 August 2017

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Molecular, biochemical, and cellular pharmacology of pemetrexed

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Thymidine Rescue: An Antidote for Pemetrexed-Related Toxicity in the Setting of Acute Renal Failure

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Pemetrexed disodium, a novel antifolate with multiple targets

1 reference

https://api.crossref.org/works/10.1080%2F07357900600629567

21 January 2018

Identifiers

10.1080/07357900600629567

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36523494&oldid=1636684458"